<DOC>
	<DOCNO>NCT01071694</DOCNO>
	<brief_summary>This study describe quality life Korean patient early relapsing-remitting multiple sclerosis initial 1 year treatment Betaferon several validate questionnaire .</brief_summary>
	<brief_title>QOLBET Quality Of Life Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferonÂ® Korea</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Relapsingremitting MS ( RRMS ) patient within first two year diagnosis accord Poser McDonald criterion , start Betaferon treatment , include patient switch DMDs Patients sign informed consent form Age low 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Multiple Sclerosis ,</keyword>
	<keyword>Relapsing-Remitting ,</keyword>
	<keyword>Interferon beta-1b ,</keyword>
	<keyword>Quality life</keyword>
</DOC>